A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

NCT04384666 | Completed Phase 1 FDA Drug

• 1 other identifier: LY03003/CT-USA-106
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open-label, 2-sequence, 2-treatment cross-over study in healthy adult subjects. Rotigotine PK profiles will be obtained from all subjects after both a single dose of 28 mg LY03003 and 1 week of 4 mg q24h NEUPRO® patch. Subjects will be randomized 1:1 to 1 of the 2 treatment sequences.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Cmax

  34 days

Secondary Outcomes (1)

• Adverse Events

  34 days

Study Arms (2)

LY03003

EXPERIMENTAL

LY03003 28 mg

Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)

Neupro 4Mg/24Hr Transdermal Patch

ACTIVE COMPARATOR

Neupro 4 mg / 24 Hr. Transdermal Patch

Other: Neupro 4 mg / 24 Hr. Transdermal Patch

Interventions

LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection) DRUG

LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)

LY03003

Neupro 4 mg / 24 Hr. Transdermal Patch OTHER

Neupro 4 mg /24 Hr. Transdermal Patch

Neupro 4Mg/24Hr Transdermal Patch

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Willing and capable of giving informed consent;
• Between the ages of 18 and 45 years old, inclusive;
• Healthy, per investigator's judgment, based on detailed medical history, clinical laboratory safety tests, vital signs, full physical examination, and ECG;
• Nonsmoker defined as not having smoked or used any form of tobacco within 6 months before screening;
• BMI between 18.5 and 30 kg/m2, inclusive, and body weight ≥50 kg at screening;
• Willing and able to comply with study procedures, adhere to study restrictions, and stay at the CRU during in-subject stays required by the protocol;
• All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at screening. In addition, female subjects must meet 1 of the following 3 conditions: (i) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of contraception include an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable contraception method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success. Highly effective methods of contraception must be used for at least 21 days prior to study drug dosing, throughout the study, and for another 90 days after the end of the study to minimize the risk of pregnancy.
• All male subjects must be willing to use a condom in combination with another acceptable form of contraception (such as partner's use of a cap, diaphragm, sponge, spermicide, or hormonal contraception. Of note, male and female condom combination is NOT acceptable)during any sexual activity (e.g. vaginal, anal, oral) with women with childbearing potential (WOCBP) even if the subjects have undergone a successful vasectomy or if their partner is already pregnant or breastfeeding, from study drug dosing, throughout the study, and for another 90 days after the end of study.

You may not qualify if:

• History of symptomatic orthostatic hypotension with a decrease of ≥20 mmHg in systolic blood pressure (SBP) or decrease of ≥10 mmHg in diastolic blood pressure (DBP) when changing from a supine to a standing position after having been in the supine position for at least 5 minutes or SBP less than 105 mmHg in a supine position at screening and Baseline;
• Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, and/or lipid metabolism disorders, and/or drug hypersensitivity;
• History of epilepsy, seizures as an adult, lifetime history of stroke, or transient ischemic attack (TIA) within 1 year prior to screening and Baseline;
• History of sleep attacks or narcolepsy;
• Known or suspected malignancy within 5 years with the exception of treated and cured basal cell carcinoma (skin), squamous cell carcinoma (skin), or in-situ cervical carcinoma;
• Positive blood screen for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
• Positive pregnancy test result or plan to become pregnant if female;
• Hospital admission or major surgery within 30 days prior to screening and Baseline;
• Receipt of another investigational product within one month or 5 half-lives of the other investigational product, whichever is longer, before study drug administration in this study.
• Presence of ink tattoos of any kind in any of the designated patch application sites.
• History of prescription drug abuse or any illicit drug use within 6 months prior to screening and Baseline;
• History of alcohol abuse according to medical history within 6 months prior to screening and Baseline;
• Positive screen for alcohol, drugs of abuse and cotinine;
• Unwillingness or inability to comply with food and beverage restrictions during study participation;
• Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening and Baseline;

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

Pharmaceutical Research Associates, Inc.

Salt Lake City, Utah, 84124, United States

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

Injections, Intramuscular; Injections; rotigotine

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Ahad Sabet, MD

  Pharmaceutical Research Associates

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a randomized, open-label, 2-sequence, 2-treatment cross-over study to evaluate the rotigotine PK profiles after a single dose of 28 mg LY03003 IM injection and 7 days of 4 mg NEUPRO® patch q24h in healthy subjects. Subjects will be screened according to the inclusion and exclusion criteria (Days -28 to -1) prior to randomization. Each subject will be randomized 1:1 to 1 of the 2 treatment sequences and will participate in 2 treatment periods.

Study Record Dates

• First Submitted: May 8, 2020
• First Posted: May 12, 2020
• Study Start: June 2, 2020
• Primary Completion: August 5, 2020
• Study Completion: August 10, 2020
• Last Updated: October 14, 2020

Record last verified: 2020-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)